XML 61 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 5,530 $ 1,327
Restricted Cash 0 149
Short-term investments 5,708 0
Prepaid expenses and other current assets 367 254
Total current assets 11,605 1,730
Property and equipment, net 167 147
Right-of-use asset, net 0 48
Other assets 413 1,424
Total assets 12,185 3,349
Current liabilities:    
Accounts payable 1,419 2,866
Accrued clinical trial costs 1,141 1,143
Accrued other 1,468 572
Other current liabilities 0 199
Total current liabilities 4,028 4,780
Long-term liabilities    
Warrant liability 0 2,645
Convertible promissory notes 0 5,157
Total liabilities 4,028 12,582
Commitments and contingencies (Note 9)
Stockholders' equity (deficit) (1)    
Preferred stock [1] 0 0
Common stock [1] 1 1
Additional paid-in capital [1] 154,218 40,402
Accumulated deficit [1] (146,064) (111,707)
Accumulated other comprehensive income (loss) [1] 2  
Total stockholders' equity (deficit) [1] 8,157 (71,304)
Total liabilities, convertible preferred stock and stockholders' equity (deficit) 12,185 3,349
Series A Convertible Preferred Stock [Member]    
Convertible preferred stock    
Convertible preferred stock 0 19,107
Series B Convertible Preferred Stock [Member]    
Convertible preferred stock    
Convertible preferred stock 0 8,224
Series C-1 Convertible Preferred Stock [Member]    
Convertible preferred stock    
Convertible preferred stock 0 5,683
Series C-2 Convertible Preferred Stock [Member]    
Convertible preferred stock    
Convertible preferred stock 0 9,563
Series D Convertible Preferred Stock [Member]    
Convertible preferred stock    
Convertible preferred stock $ 0 $ 19,494
[1]

(1) Retroactively restated for the reverse recapitalization as described in Note 2.